CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
The Citizens JMP Life Sciences Conference
Fireside Chat: Tuesday, May 14, 2024 at 11:00 am ET
Location: New York, NY
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
H.C. Wainwright 2nd Annual BioConnect Investor Conference
Fireside Chat: Monday, May 20, 2024 at 10:30 am ET
Location: New York, NY
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
| Last Trade: | US$0.15 |
| Daily Change: | -0.009 -5.62 |
| Daily Volume: | 6,138,618 |
| Market Cap: | US$18.810M |
March 20, 2025 January 08, 2025 December 27, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
